To test whether the same association could be observed in clinical samples, we investigated MHC-II/HLA-DR expression by IHC in a tissue microarray (TMA) of melanoma patient samples (n=67) with known BRAF and NRAS genotypes who largely had not received immune therapy (Supplementary Table 1). This evidence concerns the gene NRAS and melanoma.